September 4, 2026

@michaelokun

Parkinson’s disease is not only costing lives and independence; it is costing Europe billions. Economic burden means the total financial impact of a disease, including medical care, lost productivity and unpaid caregiving. Welter and colleagues describe in a new paper in Movement Disorders the enormous and growing societal cost of Parkinson’s disease across Europe. Key points: - Parkinson’s disease was estimated to cost Europe €22.8 billion in 2019, equivalent to approximately €28.8 billion in 2025 after adjustment for inflation. - Direct costs accounted for 76% of the economic burden, while informal caregiving accounted for another 19%. - The prevalence rate of Parkinson’s increased 18% in the WHO European region between 2010 and 2019, suggesting the economic challenge may continue to grow. My take: Parkinson’s is not simply a tremor disease and these numbers remind us that its impact extends far beyond the clinic. Families, care partners and health systems are absorbing an enormous burden. We need better treatments, however we should also be thinking upstream about prevention and modifiable risk factors, including environmental exposures. The price of Parkinson’s should be measured not only in euros, but also in independence, caregiver time and lives disrupted. Here are 5 points that resonated w/ me: 1- More Parkinson’s means more disability, more caregiving and more pressure on health systems. 2- Informal caregiving is a major part of the Parkinson’s economy and we should never underestimate what families contribute. 3- Advanced Parkinson’s can be particularly expensive, strengthening the argument for earlier and more effective interventions. 4- Investment in disease modifying therapies could potentially yield returns both for folks living w/ Parkinson’s and for society. 5- Perhaps most importantly, we need to invest not only in treating Parkinson’s, but also in understanding why Parkinson’s is increasing and how we might prevent it. https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.70491